# Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and Function

Study · id `cardio:ct-nct03049540` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03049540](<https://clinicaltrials.gov/study/NCT03049540>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03049540

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT03049540. Randomized; quadruple masking; primary purpose supportive care. Start 2017-10-25 (actual); primary completion 2021-10-28 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose supportive care
- Phase: Phase 3
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT03049540, source copy `cardio:ctgov-nct03049540-2023-06-23`, retrieved 2026-10-26)
- Started: 2017-10-25 (actual) (ClinicalTrials.gov record NCT03049540, source copy `cardio:ctgov-nct03049540-2023-06-23`, retrieved 2026-10-26)
- Primary completion: 2021-10-28 (actual) (ClinicalTrials.gov record NCT03049540, source copy `cardio:ctgov-nct03049540-2023-06-23`, retrieved 2026-10-26)
- Completion: 2021-10-28 (actual) (ClinicalTrials.gov record NCT03049540, source copy `cardio:ctgov-nct03049540-2023-06-23`, retrieved 2026-10-26)
- Countries: Austria; Switzerland (ClinicalTrials.gov record NCT03049540, source copy `cardio:ctgov-nct03049540-2023-06-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03049540-2023-06-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and Function
- Acronym: SERVE
- Condition: Heart Defects, Congenital
- Condition: Transposition of Great Vessels With Ventricular Inversion
- Intervention (Drug): Tadalafil 20 MG
- Intervention (Drug): Placebo 20 MG
- Lead sponsor: Insel Gruppe AG, University Hospital Bern
- Lead sponsor class: OTHER
- Collaborator: Swiss National Science Foundation
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Adult congenital heart disease (`cardio:adult-congenital-heart-disease`)
- Registry condition terms include this condition: Congenital heart disease (`core:congenital-heart-disease`)
- Registry lists this organization as the lead sponsor: Insel Gruppe AG, University Hospital Bern (`cardio:org-insel-gruppe-ag-university-hospital-bern`)
- Registry lists this organization as a collaborator: Swiss National Science Foundation (`cardio:org-swiss-national-science-foundation`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Effect of phosphodiesterase-5 inhibition on SystEmic Right VEntricular size and function. A multicentre, double-blind, randomized, placebo-controlled trial: SERVE (`cardio:pubmed-37264734`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Prognostic Value and Determinants of High-Sensitivity Cardiac Troponin T in Patients With a Systemic Right Ventricle: Insights From the SERVE Trial (`cardio:pubmed-38726920`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: db4097888631f939f4a82795af569cf601ebca923643f9146e6a15732ceeea6d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
